AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaBiliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05775159
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Phase 3
Active, not recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 142
- Registration Number
- NCT05771480
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 373
- Registration Number
- NCT05755906
- Locations
- 🇿🇦
Research Site, Tygervalley, South Africa
Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants
Phase 3
Completed
- Conditions
- Mucociliary Clearance
- Interventions
- Drug: HFO MDIDrug: HFA MDI
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT05755932
- Locations
- 🇬🇧
Research Site, Glasgow, United Kingdom
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05751759
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Combination Product: PlaceboCombination Product: Tozorakimab 1Combination Product: Tozorakimab 2
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1596
- Registration Number
- NCT05742802
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Phase 2
Active, not recruiting
- Conditions
- Pulmonary Hypertension (World Health Organization Group 2)Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05737940
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)
Completed
- Conditions
- Asthma
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT05734339
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
Recruiting
- Conditions
- Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT05729711
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
© Copyright 2025. All Rights Reserved by MedPath